Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma.

Konduri V, Halpert MM, Baig YC, Coronado R, Rodgers JR, Levitt JM, Cerroni B, Piscoya S, Wilson N, DiBernardi L, Omarbekov Z, Seelhoff L, Ravi V, Douglass L, Decker WK.

Cancer Gene Ther. 2019 Sep;26(9-10):282-291. doi: 10.1038/s41417-019-0080-3. Epub 2019 Jan 23.

2.

AIMp1 Potentiates TH1 Polarization and Is Critical for Effective Antitumor and Antiviral Immunity.

Liang D, Tian L, You R, Halpert MM, Konduri V, Baig YC, Paust S, Kim D, Kim S, Jia F, Huang S, Zhang X, Kheradmand F, Corry DB, Gilbert BE, Levitt JM, Decker WK.

Front Immunol. 2018 Jan 15;8:1801. doi: 10.3389/fimmu.2017.01801. eCollection 2017.

3.

Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy.

Konduri V, Halpert MM, Liang D, Levitt JM, Cruz-Chan JV, Zhan B, Bottazzi ME, Hotez PJ, Jones KM, Decker WK.

Infect Immun. 2017 Aug 18;85(9). pii: e00127-17. doi: 10.1128/IAI.00127-17. Print 2017 Sep.

4.

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.

Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM.

Cancer Immunol Immunother. 2017 Oct;66(10):1345-1357. doi: 10.1007/s00262-017-2027-6. Epub 2017 Jun 12.

PMID:
28608115
5.

Future of fundamental discovery in US biomedical research.

Levitt M, Levitt JM.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6498-6503. doi: 10.1073/pnas.1609996114. Epub 2017 Jun 5.

6.

Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma.

Konduri V, Li D, Halpert MM, Liang D, Liang Z, Chen Y, Fisher WE, Paust S, Levitt JM, Yao QC, Decker WK.

Oncoimmunology. 2016 Jul 22;5(9):e1213933. eCollection 2016.

7.

MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.

Collinson-Pautz MR, Slawin KM, Levitt JM, Spencer DM.

PLoS One. 2016 Oct 14;11(10):e0164547. doi: 10.1371/journal.pone.0164547. eCollection 2016.

8.

Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7.

Halpert MM, Konduri V, Liang D, Chen Y, Wing JB, Paust S, Levitt JM, Decker WK.

Stem Cells Dev. 2016 May 15;25(10):774-87. doi: 10.1089/scd.2016.0009. Epub 2016 May 2.

9.

Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.

von Rundstedt FC, Rajapakshe K, Ma J, Arnold JM, Gohlke J, Putluri V, Krishnapuram R, Piyarathna DB, Lotan Y, Gödde D, Roth S, Störkel S, Levitt JM, Michailidis G, Sreekumar A, Lerner SP, Coarfa C, Putluri N.

J Urol. 2016 Jun;195(6):1911-9. doi: 10.1016/j.juro.2016.01.039. Epub 2016 Jan 21.

10.

The preclinical activity of lenalidomide in indolent urothelial carcinoma.

Jian W, Levitt JM, Lerner SP, Sonpavde G.

Anticancer Res. 2014 Jul;34(7):3383-9.

PMID:
24982344
11.

The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma.

Jian W, Levitt JM, Lerner SP, Sonpavde G.

Anticancer Res. 2014 Jul;34(7):3377-82.

PMID:
24982343
12.

Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.

Jian W, Xu HG, Chen J, Xu ZX, Levitt JM, Stanley JA, Yang ES, Lerner SP, Sonpavde G.

Anticancer Drugs. 2014 Sep;25(8):878-86. doi: 10.1097/CAD.0000000000000114.

PMID:
24714082
13.

FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Carstens JL, Shahi P, Van Tsang S, Smith B, Creighton CJ, Zhang Y, Seamans A, Seethammagari M, Vedula I, Levitt JM, Ittmann MM, Rowley DR, Spencer DM.

Cancer Res. 2014 Jan 15;74(2):609-20. doi: 10.1158/0008-5472.CAN-13-1093. Epub 2013 Dec 4.

14.

Superresolution microscopy with quantum emitters.

Schwartz O, Levitt JM, Tenne R, Itzhakov S, Deutsch Z, Oron D.

Nano Lett. 2013;13(12):5832-6. doi: 10.1021/nl402552m. Epub 2013 Nov 11.

PMID:
24195698
15.

Colloidal quantum dots as saturable fluorophores.

Schwartz O, Tenne R, Levitt JM, Deutsch Z, Itzhakov S, Oron D.

ACS Nano. 2012 Oct 23;6(10):8778-82. doi: 10.1021/nn302551v. Epub 2012 Oct 4.

PMID:
22992215
16.

Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Kemnade JO, Seethammagari M, Narayanan P, Levitt JM, McCormick AA, Spencer DM.

Mol Ther. 2012 Jul;20(7):1462-71. doi: 10.1038/mt.2012.48. Epub 2012 Mar 20.

17.

Automated biochemical, morphological, and organizational assessment of precancerous changes from endogenous two-photon fluorescence images.

Levitt JM, McLaughlin-Drubin ME, Münger K, Georgakoudi I.

PLoS One. 2011;6(9):e24765. doi: 10.1371/journal.pone.0024765. Epub 2011 Sep 9.

18.

The E3 ligase c-Cbl regulates dendritic cell activation.

Chiou SH, Shahi P, Wagner RT, Hu H, Lapteva N, Seethammagari M, Sun SC, Levitt JM, Spencer DM.

EMBO Rep. 2011 Sep 1;12(9):971-9. doi: 10.1038/embor.2011.143.

19.

A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.

Levitt JM, Jian W, Lerner SP, Sonpavde G.

Urol Oncol. 2013 Feb;31(2):234-40. doi: 10.1016/j.urolonc.2010.11.004. Epub 2011 Jul 1.

PMID:
21723160
20.

A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.

Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM.

J Clin Invest. 2011 Apr;121(4):1524-34. doi: 10.1172/JCI44327. Epub 2011 Mar 7.

21.

The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function.

Ramachandran IR, Song W, Lapteva N, Seethammagari M, Slawin KM, Spencer DM, Levitt JM.

J Immunol. 2011 Apr 1;186(7):3934-45. doi: 10.4049/jimmunol.1001675. Epub 2011 Feb 25.

22.

Single-beam coherent Raman spectroscopy and microscopy via spectral notch shaping.

Katz O, Levitt JM, Grinvald E, Silberberg Y.

Opt Express. 2010 Oct 25;18(22):22693-701. doi: 10.1364/OE.18.022693.

PMID:
21164608
23.

Emerging vaccine therapy approaches for prostate cancer.

Sonpavde G, Slawin KM, Spencer DM, Levitt JM.

Rev Urol. 2010 Winter;12(1):25-34.

24.

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.

Levitt JM, Yamashita H, Jian W, Lerner SP, Sonpavde G.

Mol Cancer Ther. 2010 May;9(5):1128-35. doi: 10.1158/1535-7163.MCT-10-0096. Epub 2010 Apr 20.

25.

Best practices for mental health in child welfare: screening, assessment, and treatment guidelines.

Romanelli LH, Landsverk J, Levitt JM, Leslie LK, Hurley MM, Bellonci C, Gries LT, Pecora PJ, Jensen PS; Child Welfare-Mental Health Best Practices Group.

Child Welfare. 2009;88(1):163-88.

PMID:
19653458
26.

Identification of mental health service need among youth in child welfare.

Levitt JM.

Child Welfare. 2009;88(1):27-48. Review.

PMID:
19653452
27.

Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.

Jian W, Yamashita H, Levitt JM, Lerner SP, Sonpavde G.

Mol Cancer Ther. 2009 Jul;8(7):1772-8. doi: 10.1158/1535-7163.MCT-09-0141. Epub 2009 Jun 9.

28.

Fully automated, quantitative, noninvasive assessment of collagen fiber content and organization in thick collagen gels.

Bayan C, Levitt JM, Miller E, Kaplan D, Georgakoudi I.

J Appl Phys. 2009 May 15;105(10):102042. Epub 2009 May 19.

29.
30.

Non-invasive optical characterization of biomaterial mineralization.

Gupta S, Hunter M, Cebe P, Levitt JM, Kaplan DL, Georgakoudi I.

Biomaterials. 2008 May;29(15):2359-69. doi: 10.1016/j.biomaterials.2008.01.034. Epub 2008 Mar 3.

31.

A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

Mullins C, Lucia MS, Hayward SW, Lee JY, Levitt JM, Lin VK, Liu BC, Chinnaiyan AM, Rubin MA, Slawin K, Star RA, Getzenberg RH; MPSA Consortium.

J Urol. 2008 Apr;179(4):1243-56. doi: 10.1016/j.juro.2007.11.049. Epub 2008 Feb 20. Review.

32.

Establishing ongoing, early identification programs for mental health problems in our schools: a feasibility study.

Nemeroff R, Levitt JM, Faul L, Wonpat-Borja A, Bufferd S, Setterberg S, Jensen PS.

J Am Acad Child Adolesc Psychiatry. 2008 Mar;47(3):328-338. doi: 10.1097/CHI.0b013e318160c5b1.

PMID:
18216732
33.

Diagnostic cellular organization features extracted from autofluorescence images.

Levitt JM, Hunter M, Mujat C, McLaughlin-Drubin M, Münger K, Georgakoudi I.

Opt Lett. 2007 Nov 15;32(22):3305-7.

PMID:
18026288
34.

Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation.

Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM.

Cancer Res. 2007 Nov 1;67(21):10528-37.

35.

Endogenous optical biomarkers of normal and human papillomavirus immortalized epithelial cells.

Mujat C, Greiner C, Baldwin A, Levitt JM, Tian F, Stucenski LA, Hunter M, Kim YL, Backman V, Feld M, Münger K, Georgakoudi I.

Int J Cancer. 2008 Jan 15;122(2):363-71.

36.

Implementing an evidence-based trauma treatment in a state system after September 11: the CATS project.

Hoagwood KE, Vogel JM, Levitt JM, D'Amico PJ, Paisner WI, Kaplan SJ; Child and Adolescent Trauma Treatments and Services Consortium.

J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):773-9. No abstract available.

PMID:
17513990
37.

Intrinsic fluorescence and redox changes associated with apoptosis of primary human epithelial cells.

Levitt JM, Baldwin A, Papadakis A, Puri S, Xylas J, Münger K, Georgakoudi I.

J Biomed Opt. 2006 Nov-Dec;11(6):064012.

38.

Sulfur mustard primes phagocytosis and degranulation in human polymorphonuclear leukocytes.

Vavra AK, Laurent CJ, Ngo V, Sweeney JF, Levitt JM.

Int Immunopharmacol. 2004 Mar;4(3):437-45.

PMID:
15037221
39.

Low-dose sulfur mustard primes oxidative function and induces apoptosis in human polymorphonuclear leukocytes.

Levitt JM, Lodhi IJ, Nguyen PK, Ngo V, Clift R, Hinshaw DB, Sweeney JF.

Int Immunopharmacol. 2003 May;3(5):747-56.

PMID:
12757743
40.
41.

Heterogeneity of RMA-S cell line: derivatives of RMA-S cells lacking H2-Kb and H2-Db expression.

Howell D, Levitt JM, Foster PA, Guenther MM, Shawar SM, Rich RR, Rodgers JR.

Immunogenetics. 2000 Nov;52(1-2):150-4. No abstract available.

PMID:
11132152
43.

A nomenclature solution to mouse MHC confusion.

Rodgers JR, Levitt JM, Cresswell P, Lindahl KF, Mathis D, Monaco JT, Singer DS, Ploegh HL, Bryant PW.

J Immunol. 1999 May 15;162(10):6294. No abstract available.

PMID:
10375304
44.

The conceptualization and assessment of family dynamics in terminal care.

Levitt JM.

Hosp J. 1986 Winter;2(4):1-19. No abstract available.

PMID:
3647918
45.

Microcystic dystrophy of the corneal epithelium.

Levitt JM.

Am J Ophthalmol. 1971 Aug;72(2):381-2. No abstract available.

PMID:
5315213
46.

Keratomycosis due to Allescheria boydii.

Levitt JM, Goldstein J.

Am J Ophthalmol. 1971 Jun;71(6):1190-1. No abstract available.

PMID:
5104573
47.

Clostridium perfringens panophthalmitis.

Levitt JM, Stam J.

Arch Ophthalmol. 1970 Aug;84(2):227-8. No abstract available.

PMID:
4317780
48.

Orbital nodular fasciitis.

Levitt JM, deVeer JA, Oguzhan MC.

Arch Ophthalmol. 1969 Feb;81(2):235-7. No abstract available.

PMID:
5764687
49.

Hereditary changes in skin of the eyelids.

LEVITT JM.

Arch Ophthalmol. 1959 Sep;62:506-7. No abstract available.

PMID:
14416339
50.

Lacrimal air anomalies.

LEVITT JM, KRAVITZ D.

AMA Arch Ophthalmol. 1959 Jan;61(1):9-13. No abstract available.

PMID:
13605331

Supplemental Content

Loading ...
Support Center